Exosome Drug Developer Capricor Therapeutics Inc (CAPR) is Initiated by ROTH Capital to Buy

June 16, 2016 Leave a comment 2,023 Views

from The Market Digest by Robert Westfall Capricor Therapeutics Inc (CAPR) was Initiated by ROTH Capital to “Buy”. ROTH Capital advised their investors in a research report released on Jun 15, 2016. Capricor Therapeutics Inc opened for trading at $3.31 ...

Exosome RNA Exosome RNA Research & Industry News

Tag Archives: CSps

Exosome Drug Developer Capricor Therapeutics Inc (CAPR) is Initiated by ROTH Capital to Buy

Bone regeneration with exosomes coated 3D-scaffold

Cascade signal amplification for sensitive detection of exosomes by integrating tyramide and surface-initiated enzymatic polymerization

One-stop Exosome Characterization Services Are Updated at Creative Biolabs

Scaled isolation of mesenchymal stem/stromal cell-derived extracellular vesicles

A urine-based exosomal gene expression test stratifies risk of high-grade prostate cancer in men with prior negative prostate biopsy undergoing repeat biopsy

RAB31 has dual functions in the biogenesis of exosomes